

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**廣州藥業股份有限公司**

**Guangzhou Pharmaceutical Company Limited**

*(a joint stock company with limited liability established in the People's Republic of China)*

(H Share Stock Code: 0874)

**ANNOUNCEMENT  
ON CHANGE OF THE SPONSOR REPRESENTATIVE  
OF THE SHARE REFORM**

Guangzhou Pharmaceutical Company Limited (the “Company”) and all members of the Board of Directors (the “Board”) collectively and individually accept full responsibility for the authenticity, accuracy and completeness of the information contained in this announcement and confirm that there are no false information, misleading statements or material omissions in this announcement.

This announcement is made pursuant to Rule 13.09 (2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The Company was recently notified by Guotai Junan Securities Co., Ltd. (“Guotai Junan”), the Sponsor of the Share Reform of the Company (the “Share Reform”), that owing to the work relocation of Mr. Wang Wenyi, the previous Sponsor representative of the Company, Guotai Junan has appointed Mr. Shi Jijun as the Sponsor representative of the Company in place of Mr. Wang Wenyi to perform the continuous supervision and instruction duties regarding the Share Reform.

The Board of  
**Guangzhou Pharmaceutical Company Limited**

Guangzhou, the PRC, 5 February 2009

*As at the date of this announcement, the Board comprises Mr. Yang Rongming, Mr. Shi Shaobin, Mr. Feng Zansheng as Executive Directors and Mr. Wong Hin Wing, Mr. Liu Jinxiang, Mr. Li Shanmin and Mr. Zhang Yonghua as Independent Non-executive Directors.*